Press Releases

Second quarter 2021 total revenues of $141.3 million , a 12% increase compared to 2020 Qelbree™ launched in the U.S. for pediatric ADHD at the end of May 2021 Qelbree sNDA for adult ADHD submitted to the FDA SPN-830 (apomorphine infusion pump) NDA resubmission anticipated in the second half of 2021
Posted: August 4, 2021
Qelbree™ has proven efficacy in ADHD, with improvement in symptoms as early as the first week ROCKVILLE, Md. , May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central
Posted: May 24, 2021
First quarter 2021 total revenues of $130.9 million , a 38% increase compared to 2020 Qelbree™ approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021 Qelbree sNDA submission for adult ADHD anticipated in the third quarter of 2021 SPN-830 (apomorphine infusion pump) NDA
Posted: May 5, 2021
ROCKVILLE, Md. , May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Newron Pharmaceuticals S.p.A.
Posted: May 4, 2021
Displaying 1 - 10 of 16